The chimeric antigen receptor -T therapy is a type of immunotherapy in which T-cells are taken from the patient’s blood are modified in a laboratory with the addition of a special protein receptor that grants T-cells the power to recognize as well as kill cancer cells easily, along with infusing the same back into that patient. This special protein receptor, known as the chimeric antigen receptor (CAR), attaches to a specific protein on a patient’s cancer cells. The infused cells multiply and prevail in the patient’s body as living drugs. The main types of chimeric antigen receptor -T therapy is monotherapy and combination therapy. Monotherapy is used in the treatment of any disease with a single drug. The target antigens involved are CD19, CD22, and others that are used in various applications such as acute lymphoblastic leukemia, diffuse large b-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, and others. The chimeric antigen receptor -T therapy market research report is one of a series of new reports from The Business Research Company that provides chimeric antigen receptor -T therapy market statistics, including chimeric antigen receptor -T therapy industry global market size, regional shares, competitors with a chimeric antigen receptor -T therapy market share, detailed chimeric antigen receptor -T therapy market segments, market trends and opportunities, and any further data you may need to thrive in the chimeric antigen receptor -T therapy industry. This chimeric antigen receptor -T therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global car-t therapy pipeline analysis market size grew from $1.8 billion in 2022 to $2.25 billion in 2023 at a compound annual growth rate (CAGR) of 25.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global car-t therapy pipeline analysis market size is expected to grow from $3.9 billion in 2027 at a CAGR of 14.7%. The CAR-T therapy market is driven by the increasing financial support provided by different organizations to promote the development and consumption of CAR-T therapy. The government and non-government organizations provide financial support to the companies in the CAR-T therapy market for research and development and the patients for their treatment of acute lymphoblastic leukemia (ALL). For instance, in December 2021, the University of California San Diego School of Medicine (CA, USA) was granted a funding of US$ 4.1 million for the development of novel chimeric antigen receptor (CAR-T) cell therapy. The grant was awarded by California Institute for Regenerative Medicine (CIRM; CA, USA)?governing board.The financial support provided by different organizations towards CAR-T therapy positively drives the growth of the CAR-T therapy market. The limitations on the application of CAR-T therapy limit the growth of the market. The limitations of CAR-T therapy include its failure to treat other types of cancer, side effects, and the high cost of treatment. CAR-T therapy is widely used as a treatment for a particular type of blood cancer and fails to treat other types of cancers such as lung cancer or breast cancer. Further, in many cases, the application of CAR-T therapy results in cytokine release syndrome (CRS). CRS is a severe flu-like condition causing high fever, nausea, chills, headache, rash, and troubled breathing. Further, the high cost limits the growth of the market. According to a report from Kaiser Health News, the per-patient cost of CAR-T cell therapy was more than $1 million in 2021. Thus, the growth of CAR-T therapy is restricted by the various limitations on the application of CAR-T therapy. The companies in the CAR-T therapy market are conducting clinical trials to assess the ability of CAR-T therapy to treat multiple myeloma. Multiple myeloma is a type of white blood cell cancer where the cancer cells accumulate in the bone marrow and surrounds the healthy blood cells. CAR-T therapy is being tested as a treatment for multiple myeloma. CAR-T cells are modified to target the multiple myeloma causing cells to treat the relapsed or refractory multiple myeloma (RRMM). For instance, in December 2021, Novartis announced the introduction of T-Charge™, the company’s next-generation CAR-T platform that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. The product was in the early clinical stage (Phase I). In January 2020, Astellas Pharma, a Japan-based pharmaceuticals company acquired Xyphos for $120m(€107m). The acquisition would add five pre-clinical candidates to Astellas Pharma’s portfolio. Xyphos is a US-based CAR-T cell therapy developer. Major players in the chimeric antigen receptor -T therapy market are Novartis AG, Kite Pharma, Pfizer Inc., Juno Therapeutics, Celgene Corporation, CARsgen Therapeutics, Sorrento Therapeutics, Legend Biotech, Mustang Bio, and Immune Therapeutics. North America was the largest region in the CAR-t therapy market in 2022. Western Europe was the second-largest region in the global CAR-T therapy market. The regions covered in the global chimeric antigen receptor -T therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the chimeric antigen receptor -T therapy market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The chimeric antigen receptor -T therapy market includes revenues earned by CAR-T therapy products and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global CAR-T therapy pipeline analysis market is segmented - 1) By Type: Monotherapy, Combination Therapy 2) By Target Antigen: CD19, CD22, Other Target Antigens 3) By Application: Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Other Applications

A controlled substance is a drug or chemical, such as illegally used drugs or legally prescribed pharmaceuticals, whose production, possession, or usage is governed by a government. A controlled substance medication can lead to physical and mental dependence, and its restrictions are based on the likelihood that it may be abused or lead to dependence. It can help reduce pain and other symptoms, enhancing a person's life. The main types of controlled substances and drugs are opioids, stimulants, depressants, and cannabinoids. Opioids refer to a class of drugs used to treat moderate to severe pain. It can be synthesized in the laboratory or obtained from the opium poppy plant. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used for several applications including pain management, sleep disorders, depression and anxiety, seizures, attention deficit hyperactivity disorder (ADHD), and others. The global controlled substance market is segmented - 1) By Drug: Opioids, Stimulant, Depressants, Cannabinoids 2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 3) By Application: Pain Management, Sleep Disorders, Depression And Anxiety, Seizure, Attention Deficit Hyperactivity Disorder (ADHD), Other Applications The global controlled substance market size is expected to grow from $83.92 billion in 2022 to $89.78 billion in 2023 at a compound annual growth rate (CAGR) of 7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global controlled substance market size is expected to reach $116.44 billion in 2027 at a CAGR of 6.7%. The increasing demand for medically prescribed drugs is expected to propel the growth of the controlled substance market going forward. A prescription drug refers to drugs that are intended to be used in the treatment, cure, remediation, therapeutic intervention, or avoidance of illness. Prescription drugs are commonly included in controlled substances. Prescription drugs are beneficial to the controlled substance market because they can enhance outcomes for patients and minimize wasteful spending. For instance, in February 2023, according to a report shared by the Centers for Medicare and Medicaid Services (CMS), a US-based federal agency, in 2021, spending on prescription drugs increased by 7.8 % to $378.0 billion, which is faster than the 3.7 % growth in 2020. Therefore, the increasing demand for medically prescribed drugs is driving the growth of the controlled substance market. Major players in the controlled substance market are Merck & Co. Inc., Johnson and Johnson Services Inc., Orbis Biosciences Inc., GW Pharmaceuticals PLC, Corium Inc., Pfizer Inc., Aradigm Corporation, Alkermes PLC, Depomed Inc., Sun Pharmaceutical Ltd., F. Hoffmann-La Roche Ltd., AbbVie Inc., Mallinckrodt PLC, Ampac Fine Chemicals, Coating Place Inc., Siegfried Holding AG. Product innovations are a key trend gaining popularity in the controlled substance market. Major companies operating in the controlled substance market are innovating new products and drugs to sustain their position in the market. For instance, in January 2022, CMM (CareFlow Medicines Management Ltd.), a UK-based provider of medicine management solutions, partnered with an Australia-based healthcare software provider, Modeus, to launch its Controlled Drug Manager (CD Manager). It is an innovative controlled drug management platform designed to safely manage and track controlled drugs, including patients own drugs. The brand-new CMM CD Manager, powered by Modeus, will be able to interact with both CMM's platform for managing medications and other external systems. It has been created for usage by clinical personnel and pharmacists in the pharmacy, wards, and theatres of hospitals where regulated medications are kept. Using built-in reporting, CD Manager specifically assists Controlled Drug Accountable Officers in tracking the life cycle of controlled drugs within an organization and taking prompt action in response to automated warnings on inconsistencies or probable diversion. In November 2021, ANI Pharmaceuticals Inc., a US-based pharmaceutical company, acquired Novitium Pharma for $163.5 million. With this acquisition, ANI Pharmaceuticals Inc aims to strengthen its research and development engine, expand its generics and contract development and manufacturing organization (CDMO)businesses, and establish a highly compliant US production facility. Novitium Pharma is a US-based pharmaceutical company and bulk manufacturer of basic class(es) of controlled substance(s). North America was the largest region in the controlled substance market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global controlled substance market report during the forecast period. The regions covered in the global controlled substance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the controlled substance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The controlled substance market consists of sales of morphine, valium, ritalin, heroin, cannabis, diazepam, flunitrazepam, and ketamine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The controlled substances market research report is one of a series of new reports from The Business Research Company that provides controlled substances market statistics, including controlled substances industry global market size, regional shares, competitors with a controlled substances market share, detailed controlled substances market segments, market trends and opportunities, and any further data you may need to thrive in the controlled substances industry. The controlled substances market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug formulation is defined as the process of combining several chemical and biological ingredients, including the active medicine, to create a finished pharmaceutical product. It is used to be modify and optimize the drugs during the preclinical stage and initial research. The main types of dosage forms for drug formulations are oral formulations, parenteral formulations, topical formulations, and inhalation formulations. Oral formulation is defined as the development and manufacturing of pharmaceuticals designed for oral delivery. They have different formulations forms, such as tablets, capsules, injectables, sprays, suspensions, powders, and others, that are used in cardiovascular diseases (CVDs), pain, diabetes, cancer, respiratory diseases, and others. These are used by several end-users, including big pharma companies, small and medium enterprises, and biotech companies. The global drug formulation market is segmented - 1) By Dosage Form: Oral formulations, Parenteral Formulations, Topical Formulations, Inhalation Formulations 2) By Formulation: Tablets, Capsules, Injectable, Sprays, Suspensions, Powders, Other Formulations 3) By Therapy Area: Cardiovascular Diseases (CVDs), Pain, Diabetes, Cancer, Respiratory Diseases, Other Diseases 4) By End-User: Big Pharma, Small And Medium Pharma, Biotech Companies The global drug formulation market size is expected to grow from $1,640.73 trillion in 2022 to $1,780.87 trillion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drug formulation market size is expected to reach $2,444.87 trillion in 2027 at a CAGR of 8.2%. The rising prevalence of chronic diseases is expected to propel the growth of the drug formulation market going forward. Chronic diseases can be defined as conditions that last 1 year or more and require ongoing medical attention, limit activities of daily living, or both. Drug formulation has the potential to reduce the prevalence of chronic illnesses where multiple drug delivery methods are utilized to optimize therapeutic efficacy while minimizing adverse effects by influencing medication absorption, distribution, metabolism, and excretion. For instance, in September 2022, according to a report published by the National Institutes of Health (NIH), a US-based biomedical research agency, in 2023, in the United States, the number of people aged 50 and older with at least one chronic illness is predicted to rise by 99.5%, from 71.522 million in 2020 to 142.66 million in 2050. Additionally, the number of people with multimorbidity would rise by 91.16% from 7.8304 million in 2020 to 14.968 million in 2050. Therefore, the rising prevalence of chronic diseases is driving the growth of the drug formulation market. Major players in the drug formulation market are AstraZeneca PLC, The Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., C.H. Boehringer Sohn AG & Co. KG, F. Hoffmann-La Roche AG, Johnson & Johnson, 3M Company, Bayer AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline PLC, and Boston Scientific Corporation. Technological advancements are a key trend gaining popularity in the drug formulation market. Major players operating in the drug formulation market are concentrating their efforts on introducing new and advanced technologies to strengthen their position in the market. For instance, in June 2022, Merck & Co., Inc., a US-based pharmaceutical company, launched Merck Digital Sciences Studio (MDSS) to make it possible to create innovative technologies for drug research and development. Merck uses Azure Clouds robust computing and Merck's discovery and clinical experts to collaboratively accelerate and take over novel and innovative digital technologies. MDSS is a collaboration between Merck and the New Jersey Innovation Institute (NJII), a US-based company owned by the New Jersey Institute of Technology. The Merck Global Health Innovation Fund, Northpond Ventures, and McKesson Ventures have all invested in the project. Microsoft will provide start-up companies with technology support. In July 2021, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, acquired Alexion Pharmaceuticals Inc. for approximately $13.3 billion. With this acquisition, AstraZeneca enters the market for medications for uncommon disorders. AstraZeneca now has a stronger scientific presence in immunology because of Alexion's cutting-edge complement-biology platform and substantial pipeline. Alexion Pharmaceuticals Inc. is a US-based pharmaceutical company that formulates, develops, and commercializes several drugs. North America was the largest region in the drug formulation market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global drug formulation market report during the forecast period. The regions covered in the global drug formulation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug formulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The drug formulation market includes revenues earned by entities by providing formulation optimization, process optimization, and scale-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The drug formulation market research report is one of a series of new reports from The Business Research Company that provides drug formulation market statistics, including drug formulation industry global market size, regional shares, competitors with a drug formulation market share, detailed drug formulation market segments, market trends and opportunities, and any further data you may need to thrive in the drug formulation industry. This drug formulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Controlled release drug delivery refers to a dosage form that administers a medicine or medication in a specified way. This drug delivery method continuously delivers pharmaceuticals or medications in predictable kinetics for the predetermined time. The main types of technology used in controlled release drug delivery are the wurster technique, coacervation, micro encapsulation, implants, transdermal, targeted delivery, and others. The wurster technique, often referred to as fluid bed microencapsulation is the encapsulation of discrete particles in a fluidized bed employing differential air flow to produce cyclic movement of material. It involves several release mechanisms such as polymer-based systems, micro-reservoir partition-controlled drug delivery systems, feedback-regulated drug delivery systems, activation-modulated drug delivery systems, and chemically activated, which are used in applications such as metering dose inhalers, injectables, transdermal and ocular patches, and others. Major end-users include hospitals, clinics, personal, research, and others. The global controlled release drug delivery market is segmented - 1) By Technology: Wurster Technique, Coacervation, Micro Encapsulation, Implants, Transdermal, Targeted Delivery, Other Technologies 2) By Release Mechanism: Polymer Based Systems, Micro Reservoir Partition Controlled Drug Delivery Systems, Feedback Regulated Drug Delivery Systems, Activation-Modulated Drug Delivery Systems, Chemically Activated, 3) By Application: Metered Dose Inhalers, Injectable, Transdermal and Ocular Patches, Other Applications 4) By End User: Hospitals, Clinics, Peronal, Research, Other End Users The global controlled release drug delivery market size is expected to grow from $52.93 billion in 2022 to $59.20 billion in 2023 at a compound annual growth rate (CAGR) of 11.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global controlled release drug delivery market size is expected to reach $92.60 billion in 2027 at a CAGR of 11.8%. The rising prevalence of chronic diseases is expected to propel the growth of the controlled release drug delivery market. Chronic diseases are also known as noncommunicable diseases. It refers to conditions such as heart disease, cancer, and diabetes diseases lasting more than a year and requiring continuing medical care, limiting everyday activities, or both. Controlled-release drug delivery is crucial for treating chronic diseases. For patients with chronic illnesses that require years of treatment or those who reside in areas with limited resources and access to healthcare, drug delivery formulations that allow prolonged medication release are essential. For instance, in September 2022, according to report shared by the World Health Organization (WHO), a Switzerland-based health-specialized agency, every year, 41 million people die from chronic diseases, which accounts for 74 percent of all fatalities worldwide. Before the age of 70, 17 million individuals lose their lives to chronic illnesses. Moreover, 77 percent of deaths from chronic diseases occur in low- and middle-income nations. And these numbers are expected to rise in the future. Therefore, the rising prevalence of chronic diseases is driving the growth of the controlled release drug delivery market. Major players in the controlled release drug delivery market are Johnson And Johnson, Merck And Co. Inc., Alkermes Plc., Coating Place Inc., Corium International Inc., Depomed Inc., Pfizer Inc., Aradigm Corporation, Capsugel, GlaxoSmithKline Plc., Bayer Healthcare LLC, Collegium Pharmaceuticals, GE Healthcare, Adare Pharma Solutions, Allergan Plc., and Novartis AG. Technological advancement is a key trend gaining popularity in the controlled-release drug delivery market. Major companies operating in the controlled-release drug delivery market are adopting new technologies to sustain their position in the market. For instance, in October 2020, Evonik Industries AG, a Germany-based pharmaceutical manufacturer, launched Eudratec Fasteric, an oral drug delivery technology that increases gastric resistance and improves intestinal absorption for oral drug products that target sites in the upper small intestine, where there is a narrow absorption window. Moreover, it may be processed quickly and easily using common tools and is appropriate for use with a variety of oral dosage forms, including multiarticulate, tablets, and capsules. In May 2020, Adare Pharmaceutical Inc., a US-based pharmaceutical company that provides advanced pharmaceutical technologies, acquired Orbis Biosciences Inc., for an undisclosed amount. With these acquisition, Adare Pharmaceutical Inc hopes to extend its platforms to create drug particles that can be dosed in oral liquid, intravenous, and otic dosage forms and widen its product offerings. Orbis Biosciences Inc. is a US-based biotech company that develops controlled-release delivery technologies for the oral drug, medical, chemical, and consumer product industries to improve compliance. North America was the largest region in the controlled release drug delivery market in 2022. The regions covered in the global controlled release drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the controlled release drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The controlled release drug delivery market consists of revenues earned by entities by providing services such as mucoadhesive drug delivery, implantable drug delivery, and gastro-retentive drug delivery. The market value includes the value of related goods sold by the service provider or included within the service offering. The controlled release drug delivery market also includes sales of nebulizers, infusion pumps, and other systems used to provide controlled release drug delivery. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The controlled release drug delivery market research report is one of a series of new reports from The Business Research Company that provides controlled release drug delivery market statistics, including controlled release drug delivery industry global market size, regional shares, competitors with a controlled release drug delivery market share, detailed controlled release drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the controlled release drug delivery industry. This controlled release drug delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hepatitis is an inflammation of the liver caused by several viruses and non-viruses. The term hepatitis therapeutics describes the drugs that are used to treat all forms of hepatitis. The two drugs used to treat hepatitis are immune modulators and oral antivirals. The main disease types treated using hepatitis therapeutics include hepatitis A, hepatitis B, hepatitis C and other disease types. Hepatitis A refers to liver inflammation that can result in mild to severe sickness. They are classified based on drug class into oral antivirals and immune modulators and are distributed using hospital pharmacies, drug stores and retail pharmacies and online providers. The global hepatitis therapeutics market is segmented - 1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types 2) By Drug Class: Oral Antivirals, Immune Modulators 3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers The global hepatitis therapeutics market size is expected to grow from $17.87 billion in 2022 to $18.35 billion in 2023 at a compound annual growth rate (CAGR) of 2.65%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global hepatitis therapeutics market size is expected to reach $20.91 billion in 2027 at a CAGR of 3.32%. The rise in hepatitis infection globally is expected to propel the growth of the hepatitis therapeutic market going forward. The rise in hepatitis infection is due to inadequate access to healthcare and vaccinations, an increase in intravenous drug use, unsafe blood transfusion practices, and poor sanitation and hygiene conditions in some parts of the world. For instance, in April 2022, according to World Health Organization (WHO), a US-based united nations public health agency, from 11 nations, at least 169 cases of acute hepatitis of unknown origin have been documented and 350 million individuals worldwide have viral hepatitis B or C, yet for the majority, testing, and treatment are still out of reach. Therefore, the market for hepatitis therapeutics is expanding due to the rise in hepatitis infection. Major players in the hepatitis therapeutics market are Gilead Sciences Inc, Bristol-Myers Squibb Co, AbbVie Inc, Merck & Co. Inc., Johnson & Johnson Services Inc., Cipla Inc., F Hoffmann-La Roche Ltd, Biocon Limited, Roche Ltd, LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, Novartis AG, Sanofi S.A., GlaxoSmithKline Plc., Lupin Ltd. and Teva Pharmaceutical Industries Ltd. New product launches have emerged as the key trend gaining popularity in the hepatitis therapeutics market. Major companies operating in the hepatitis therapeutics market are developing new products to sustain their position in the market. For instance, in November 2022, Gilead Sciences, Inc., a US-based biopharmaceutical company received approval from FDA for a medicine called Vemlidy (tenofovir alafenamide) for the treatment of paediatric patients with chronic hepatitis B virus infection. Vemlidy is a targeted prodrug of tenofovir that received FDA approval in 2016 as a once-daily treatment for individuals with chronic hepatitis B virus (HBV) infection and compensated liver disease. According to recommendations from the American Liver Foundation, it is a preferred or first-line treatment for persons with chronic HBV and compensated liver disease. In March 2021, Gilead Sciences Inc., a US-based biopharmaceutical company acquired MYR GmbH for $1.5 billion. The acquisition provides Gilead Sciences Inc with Hepcludex (bulevirtide), which was conditionally approved by the European medicines agency for the treatment of chronic hepatitis delta virus (HDV) in adults with compensated liver disease. MYR GmbH is a Germany-based biotechnology company developing and commercializing therapeutics for the treatment of chronic B and D infections. North America was the largest region in the hepatitis therapeutics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global hepatitis therapeutics market report during the forecast period. The regions covered in the global hepatitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hepatitis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The hepatitis therapeutics market consists of revenues earned by entities by providing services such as lifestyle modifications, nutritional support, and liver transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis therapeutics market also includes sales of corticosteroids, immune globulins, and Immune globulins which are used in providing hepatitis therapeutics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The hepatitis therapeutics market research report is one of a series of new reports from The Business Research Company that provides hepatitis therapeutics optical components market statistics, including hepatitis therapeutics optical components industry global market size, regional shares, competitors with a hepatitis therapeutics optical components market share, detailed hepatitis therapeutics optical components market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis therapeutics optical components industry. This hepatitis therapeutics optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Epinephrine, also known as adrenaline, is a hormone and neurotransmitter used for life-threatening allergic reaction treatment spurred by foods, medicines, latex, insect bites or stings, and other reactions treated with epinephrine injections along with emergency medical treatment. The main types of epinephrine are prefilled syringes, auto-injector, ampoules, and vials. Prefilled syringes refer to a single-dose disposable syringe that has been pre-loaded with the medication to be administered by oneself in a single, preloaded dose of a drug. Prefilled syringes are used in the epinephrine market to eliminate the need to keep adrenaline ampoules on hand and complete the drawing-up procedure. It is distributed by various channels including hospital pharmacies, retail pharmacies, and online pharmacies for anaphylaxis, cardiac arrest, superficial bleeding, respiratory disorders, and other applications. The global epinephrine market is segmented - 1) By Type: Prefilled Syringe, Auto-injector, Ampoules and Vials 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Application: Anaphylaxis, Cardiac Arrest, Superficial Bleeding, Respiratory Disorders, Other Applications The global epinephrine market size is expected to grow from $2.20 billion in 2022 to $2.44 billion in 2023 at a compound annual growth rate (CAGR) of 11%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global epinephrine market size is expected to reach $3.49 billion in 2027 at a CAGR of 9.4%. The increase in the prevalence of chronic respiratory diseases is expected to propel the growth of the epinephrine market going forward. Chronic respiratory diseases refer to medical condition that affects the lungs and airways of the human body's respiratory system and has the potential to contract an infection or develop a disease, which can lead to a number of complications. Chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), interstitial lung disease, pulmonary sarcoidosis, and pneumoconiosis are increasing due to the prevalence of air pollution and harmful environmental, occupational, and behavioral inhalation exposures. Epinephrine is a key medication used in the treatment of severe asthma attacks and anaphylactic reactions, which can cause respiratory distress and potentially life-threatening complications. For instance, according to the data published by The Pan American Health Organization (PAHO) in 2020, a specialized UN body in responsibility for fostering global health cooperation in the Americas, the deaths caused by respiratory diseases in the US increased from 38.9 deaths per 1 million population in 2018 to 39.1 deaths per 1 million population in 2019. As the prevalence of chronic respiratory diseases continues to increase, the demand for epinephrine is also expected to grow. Major players in the epinephrine market are ALK-Abelló A/S, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Abbott Laboratories, Sanofi S.A., Viatris Inc., Lincoln Medical Ltd., Kaleo Inc., Gland Pharma Limited, Adamis Pharmaceuticals Corporation, Harvest Pharmaceuticals Inc., and Merit Pharmaceutical. Product innovation is a key trend gaining popularity in the epinephrine market. Major companies operating in the epinephrine market are involved in developing new and improved advanced products, such as auto-injectors or advanced injections, to improve convenience of consumption and sustain their position in the market. In September 2021, Baxter International Inc., a US-based healthcare company, launched Premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine) after getting approved by the US Food and Drug Administration (FDA). Norepinephrine bitartrate is a convenient formulation of norepinephrine manufactured by the pharmaceutical company in dosages of 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL). Adult patients with severe, acute hypotension are prescribed norepinephrine medication to raise blood pressure. In November 2021, Marathon Asset Management, LP, a US-based investment management company, acquired Kaléo for $310 million. This acquisition is a strategic fit for the expansion of Kaléo's services in serving patients at risk for anaphylaxis and other serious and life-threatening ailments, utilizing Marathon’s experienced management team among allergists. Kaléo is a US-based pharmaceutical company focused on innovative healthcare products including epinephrine injections. North America was the largest region in the epinephrine market in 2022. The regions covered in the global epinephrine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the epinephrine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The epinephrine market consists of sales of dl-Epinephrine and methyl epinephrine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The epinephrine market research report is one of a series of new reports from The Business Research Company that provides epinephrine market statistics, including the epinephrine industry's global market size, regional shares, competitors with an epinephrine market share, detailed epinephrine market segments, market trends, and opportunities, and any further data you may need to thrive in the epinephrine industry. This epinephrine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Male hypogonadism is a disease in which the body produces insufficient amounts of the hormone testosterone. Testosterone is the primary male sex hormone and is essential for the development and growth of men throughout puberty. The main types of male hypogonadism are klinefelter syndrome, kallmann syndrome, pituitary disorders, and others. Klinefelter syndrome refers to a hereditary disorder that develops in boys when they have an extra copy of the X chromosome at birth. The drugs are delivered through topical gels, injectable, transdermal patches, and others for testosterone therapy, and gonadotropin-releasing hormone therapy. The global male hypogonadism market is segmented - 1) By Type: Klinefelters Syndrome, Kallmann Syndrome, Pituitary Disorders, Other Types 2) By Drug Delivery: Topical Gels, Injectables, Transdermal Patches, Other Drug Deliveries 3) By Therapy: Testosterone Therapy, Gonadotropin-Releasing Hormone Therapy The global male hypogonadism market size is expected to grow from $3.32 billion in 2022 to $3.55 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global male hypogonadism market size is expected to reach $4.48 billion in 2027 at a CAGR of 6.0%. The increase in infertility rates is expected to propel the growth of the male hypogonadism market going forward. Infertility refers to a condition affecting the male or female reproductive system that is characterized by the inability to conceive after 12 months or longer of frequent, unprotected sexual activity. Male hypogonadism, which can lead to decreased sperm production and infertility, is one of the potential causes of male infertility. As a result, the increasing prevalence of male infertility is expected to drive the growth of the male hypogonadism market. For instance, in October 2021, according to the Office for National Statistics, a UK-based statistics authority, in England and Wales, there were 613,936 live births in 2020, a significant 4.1% drop from 2019. In 2020, the total fertility rate (TFR) fell to a historic low of 1.58 children per woman. As a result, the infertility rate increased from 2019 to 2020. Also, according to a 2021 study published by the Libyan Journal of Medical Sciences, around 70% of infertility is attributed to male factors in Libya. Therefore, an increase in the infertility rate is driving the growth of the male hypogonadism market. Major players in the male hypogonadism market are Allergan plc, Pfizer Inc., Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Merck & Co. Inc., Ferring Pharmaceuticals, Finox Biotech, Teva Pharmaceutical Industries Ltd., AbbVie Inc, Perrigo Company plc, AstraZeneca PLC, IBSA Institut Biochimique SA, Juniper Laboratories SA, and Sun Pharmaceutical Industries Limited. Product innovations are a key trend gaining popularity in the male hypogonadism market. Companies operating in the male hypogonadism market are innovating new products to sustain their position in the market. For instance, in June 2022, Halozyme, a US-based biotechnology company, launched Tlando, an oral treatment for testosterone replacement therapy of male hypogonadism. Tlando is a prescription drug that contains testosterone, and it is the first oral testosterone treatment approved by FDA. It is used to treat adult men who, as a result of certain medical disorders, have low or no testosterone. In July 2022, Gruenenthal, a Germany-based pharmaceutical company acquired Nebido from Bayer AG for €500 million ($551.32 million). This acquisition aimed at improving Gruenenthal’s profitability, allowing it to invest in research and development and create the next generation of pain therapies. Bayer AG is a Germany-based pharmaceutical company operating in the male hypogonadism treatment. North America was the largest region in the male hypogonadism market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global male hypogonadism market report during the forecast period. The regions covered in the global male hypogonadism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the male hypogonadism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The male hypogonadism market includes revenues earned by entities through hormone testing, semen analysis, pituitary imaging, genetic studies, and testicular biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The male hypogonadism market research report is one of a series of new reports from The Business Research Company that provides male hypogonadism market statistics, including male hypogonadism industry global market size, regional shares, competitors with a male hypogonadism market share, detailed male hypogonadism market segments, market trends, and opportunities, and any further data you may need to thrive in the male hypogonadism industry. This male hypogonadism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Minimal residual disease testing refers to a very sensitive test to detect cancer cells in the patient's body that may remain after treatment. It is used to monitor the effectiveness of cancer treatment and inform future treatment strategies. The main test types of minimal residual disease testing are DNA - based tests, RNA- based tests, and immunological tests. DNA (deoxyribonucleic acid)-based testing (also known as genetic testing) is a type of medical examination that can spot changes to your chromosomes, genes, or proteins. The various technologies include flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others, are used in various applications such as hematological malignancies, leukemia, lymphoma, solid tumors, and others. These are used by hospitals and specialty clinics, diagnostic laboratories, academic and research institutes, and others. The global minimal residual disease testing market is segmented - 1) By Test Type: DNA - Based Test, RNA- Based Test, Immunological Test 2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies 3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application 4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic and Research Institutes, Other End Users The global minimal residual disease testing market size is expected to grow from $1.22 billion in 2022 to $1.41 billion in 2023 at a compound annual growth rate (CAGR) of 14.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global minimal residual disease testing market size is expected to reach $2.32 billion in 2027 at a CAGR of 13.3%. The increasing prevalence of cancer is expected to propel the growth of the minimal residual disease testing market going forward. Cancer refers to a condition when a few of the body's cells grow out of control and spread to other bodily regions. Cancer stages are primarily detected through minimal residual disease testing, which is a very sensitive method to detect cancer cells in the human body. It helps cancer patients prevent the disease at an early stage, boosting the minimal residual disease testing market. For instance, in February 2022, according to the reports shared by the World Health Organization (WHO), a Switzerland-based health agency, cancer will be the most common cause of death worldwide. In 2020, according to the World Cancer Fund Research International, a UK-based a not-for-profit association related to cancer prevention, there were 18,094,716 million new cases of cancer worldwide. Additionally, in 2020, globally, nearly 10 million people died due to cancer, which is nearly one in six deaths. Therefore, the increasing prevalence of cancer is driving the growth of the minimal residual disease testing market. Major players in the minimal residual disease testing market are Natera Inc., Guardant Health, Laboratory Corporation of America Holdings, QIAGEN N.V, F. Hoffmann-La Roche Ltd, Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC., Veracyte Inc., Cergentis B.V, Mdxhealth, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers, and PerkinElmer Inc. Product innovations are a key trend gaining popularity in the minimal residual disease testing market. Major companies operating in the minimal residual disease testing market are innovating new products to sustain their position in the market. For instance, in 2022, Twist Bioscience, a US-based synthetic biology and genomics company, launched Twist MRD Panel to advance research and development in minimal residual disease (MRD) detection in cancer screening. Twist MRD Panel is a customizable panel of genes that can be used to detect very low levels of residual cancer cells in a patient's blood. The Twist MRD Panel is designed to be highly flexible and customizable that can be integrated into a typical next-generation sequencing (NGS) workflow that can find minimum residual disease (MRD) in just five days. In August 2021, Illumina Inc., a US-based biotechnology company, acquired GRAIL for $8 billion. With this acquisition, Illumina Inc. fastened its patient access to a life-saving multi-cancer early-detection test and expand its health services at the global level. GRAIL is a US-based biotechnology company that detects cancer at an early stage using the power of next-generation sequencing testing technology and minimal residual disease testing. North America was the largest region in the minimal residual disease testing market in 2022. The regions covered in the global minimal residual disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the minimal residual disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The minimal residual disease testing market includes revenues earned by entities by providing services such as peripheral blood cell testing, sequencing testing, high-throughput sequencing testing, and methylation sequencing testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The minimal residual disease testing market research report is one of a series of new reports from The Business Research Company that provides minimal residual disease testing market statistics, including minimal residual disease testing industry global market size, regional shares, competitors with a minimal residual disease testing market share, detailed minimal residual disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the minimal residual disease testing industry. This minimal residual disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.